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Current clinical practice lacks an accurate predictor for the pathological fracture risk in metastatic bone
disease, but biomechanical tools are under development to improve these predictions. In this paper we
explain the limitations of currently used clinical guidelines and provide an overview of more objective
and quantitative approaches that have been proposed for fracture risk assessment in metastatic bone
disease. Currently, such mechanical models are as sensitive and speciﬁc as clinical guidelines, but there
are a number of opportunities to further improve their predictive capacity. Hence, they are a promising
tool to decrease the numbers of over- and undertreated patients.
& 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Bone is a preferred organ for primary tumour cell seeding in
common cancer types such as breast, prostate, lung, kidney and
thyroid cancer (Coleman, 1997, 2006; Gralow et al., 2013; Laitinen
et al., 2012). Particularly skeletal parts that contain bone marrow
(e.g. the skull, ribs, spine, and long bones of the axial skeleton)
provide a fertile environment for seeding and are therefore com-
monly invaded by tumour cells (Johnson and Knobf, 2008; Laitinen
et al., 2012; Mavrogenis et al., 2012). In more progressive states bone
metastases can, amongst others, cause pathological fractures
(Coleman, 1997; Laitinen et al., 2012; Mantyh, 2013), in which case
patients lose their full mobility and may develop severe complica-
tions (Mavrogenis et al., 2012; Ruggieri et al., 2010). Pathological
fractures are treated with complex surgical procedures. Surgeons
have to weigh the impact of the operation and rehabilitation against
the physical status and expected survival of the patient (Attar et al.,
2012). In addition, they must be convinced that the load capacity
of the reinforced bone will sustain the daily loads for the life expec-
tancy of the patient (Attar et al., 2012). In current clinical practice,
metastatic lesions identiﬁed with an impending fracture are treated
with preventive surgery. This treatment is less complex and has
better survival rates than surgical treatment of actual pathological
fractures (Laitinen et al., 2012; Mavrogenis et al., 2012; Ratasvuori
et al., 2013). Lesions that do not jeopardise the mechanical integrity
of the bone are treated conservatively with (a combination of)
radiation therapy, analgesics, chemotherapy, hormonal therapy or
bisphosphonates, with the aim to relieve pain (Van der Linden,
2005). However, it turns out to be extremely difﬁcult, if not
impossible, to assess clinical fracture risks based on conventional
X-rays or CT images. Hence, even for experienced clinicians, it is
impossible to make accurate predictions. This was well demonstrated
in a study by Hipp et al. (1995). They used 10 paired cadaver femurs,
with an artiﬁcial lesion drilled in one of the femurs of the pair. The
failure load for each bone and the strength reduction within a pair
was determined based on a mechanical axial loading experiment.
Using CT-scans and roentgenograms of the bones, three orthopaedic
surgeons were asked to report on the lesion size, the femoral failure
load and the strength reduction within a femoral pair. There was
moderate agreement in deﬁning the lesion size (mean difference 11%,
range 2–47%), but there was no relationship between the failure load
measured in the experiments and the failure load estimated by the
surgeons. The same disappointing result was found for the strength
reduction in the femoral pairs. In a comparable experiment we
showed very similar results. Clinical experts were asked to rank
femurs with and without artiﬁcial lesions on bone strength; the rank
correlations between experimental bone strength and predictions
by clinical experts ranged only between 0.45 and 0.53 (Fig. 2)
(Derikx et al., 2012). This demonstrates that a more quantitative
measure of bone strength in patients with metastatic bone disease is
urgently needed.
In this paper we provide an overview of more objective and
quantitative approaches that have been proposed for fracture risk
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/jbiomech
www.JBiomech.com
Journal of Biomechanics
http://dx.doi.org/10.1016/j.jbiomech.2014.12.017
0021-9290/& 2014 Elsevier Ltd. All rights reserved.
n Correspondence to: Radboud university medical center, Radboud Institute
for Health Sciences, Orthopaedic Research Laboratory, P.O. Box 9101, 6500 HB
Nijmegen, The Netherlands. Tel.: þ31 24 36 174 61; fax: þ31 24 35 405 55.
E-mail address: loes.derikx@radboudumc.nl (L.C. Derikx).
Journal of Biomechanics 48 (2015) 761–766
assessment in metastatic bone disease. We discuss their efﬁcacy
and the potential challenges that may come in with the clinical
implementation of such tools.
2. Clinical methods for fracture risk assessment in metastatic
bone disease
Finding an objective measure for fracture risk assessment of
bones with metastases has been under study for several decades. By
evaluating roentgenograms of patients who sustained a pathological
fracture, the size of the lesion (Beals et al., 1971; Cheng et al., 1980;
Harrington et al., 1976; Keene et al., 1986; Miller andWhitehill, 1984;
Snell and Beals, 1964; Van der Linden et al., 2004; Zickel and
Mouradian, 1976), the extent to which cortical bone was disrupted
by the lesion (Van der Linden et al., 2004) and the radiographic
appearance of the lesion (Beals et al., 1971; Bunting et al., 1985;
Keene et al., 1986; Miller and Whitehill, 1984; Mirels, 1989; Snell and
Beals, 1964; Van der Linden et al., 2004; Yazawa et al., 1990; Zickel
and Mouradian, 1976) have been studied as potential predictors for
the fracture risk. Pain has been included as well in these studies
(Beals et al., 1971; Fidler, 1973; Harrington et al., 1976; Keene et al.,
1986; Mirels, 1989; Parrish and Murray, 1970; Van der Linden et al.,
2004), as it was hypothesised to be a measure for loss of mechanical
strength (Mirels, 1989), or an indicator of excessive deformation
(Fidler, 1973). Despite these documented efforts, none of the studies
identiﬁed a powerful predictor for the fracture risk. The most recent
clinical study in this ﬁeld compared, amongst others, two guidelines:
Mirels' scoring system and a threshold for cortical disruption (Van
der Linden et al., 2004). Mirels' system scores the location of the
lesion, pain and the appearance and size of the lesion. Patients with
high scores need immediate surgery, while patients with low scores
can be treated conservatively. Had Mirels' scoring system been
applied to the patients in the study of van der Linden et al., none
of the impending fractures would have been missed but a large
number of patients would have undergone unnecessary surgery
(sensitivity¼1.0, speciﬁcity¼0.13). Alternatively, a threshold of 3 cm
cortical disruption was proposed to identify impending pathological
fractures. Had this method been used in Van der Linden's work,
some of the impending fractures would have been missed
(sensitivity¼0.86), but the power to identify non-fracture patients
would have increased (speciﬁcity¼0.58). Thus, the latter guideline
improved upon Mirels' scoring system but remained to have
difﬁculties preventing unnecessary surgeries.
In summary, clinical studies so far have mainly focussed on
lesion characteristics and pain, while the bone strength of the
femur was largely ignored. In order to estimate the fracture risk,
however, it is important to assess the reduction in bone strength
caused by the lesion with respect to the initial bone strength.
3. Mechanical models to assess femoral bone strength
More recently, the focus has shifted towards mechanical models
for fracture risk assessment. The most commonly proposed ones are
computed tomography based rigidity analysis (CTRA) and patient-
speciﬁc ﬁnite element (FE) modelling.
The use of composite beam theory in the context of fracture risk
assessment has been extensively investigated over the last two
decades (Leong et al., 2010; Snyder et al., 2009; Snyder et al., 2006;
Windhagen et al., 1997). Starting in the spine, Windhagen et al.
(1997) generated quantitative CT (QCT) scans from vertebral seg-
ments with artiﬁcial and actual metastatic lesions and mechanically
loaded them until fracture. Using a calibration phantom, the grey
values in the CT scans were converted to ash densities and Young's
moduli, respectively, and the axial rigidity for every CT slice was
subsequently calculated based on composite beam theory. High
correlations were found between the experimental failure load and
axial rigidity (R2 ranging from 0.79 to 0.85). No correlation was
found between defect size and failure load, which conﬁrms earlier
ﬁndings showing that lesion characteristics alone cannot accurately
predict fracture risk in metastatic bone. Additionally, CTRA was
applied in the femur in a clinical setting. Snyder et al. (2006)
included 36 patients with benign femoral lesions, 18 of which had
sustained a fracture. Axial, torsional and bending rigidities were
calculated for the affected bone and the intact contralateral bone,
respectively (Fig. 1). Statistical analysis revealed no difference in
lesion characteristics between the two groups, but the relative
reduction in rigidity (i.e. the difference in rigidity between the intact
and the affected bone) was signiﬁcantly larger in the fracture group
than in the non-fracture group. Thus, in the fracture group the
lesions had weakened the bone to a larger extent than in the non-
fracture group. This was the case for axial, bending and torsional
rigidity. Based on these results, cut-off values were deﬁned, on the
Fig. 1. The left panel shows the relative reduction in bone mineral content (BMC), axial rigidity (axial), minimum bending rigidity (min bend) and torsional rigidity
(torsional) for every CT slice. This reduction is largest in the slice at location 385 mm (450% for minimum bending rigidity) and indicated with the black line in the lateral
plane (middle panel). In the right panel, the affected and unaffected femurs at this speciﬁc level are shown. Reprinted from (Snyder et al., 2006) with permission.
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basis of which fracture patients and non-fracture patients could
be accurately distinguished (sensitivity¼1, speciﬁcity¼0.94). This
method is rather straightforward, and relatively quick, but, as
acknowledged by the authors, it requires an intact contralateral
femur for calculation of the reduction in rigidity. In metastatic bone
disease, however, this contralateral femur is likely to be affected as
well, which hampers the use of this method. Moreover, the out-
come measures (axial, bending or torsional rigidities) are difﬁcult to
interpret in clinical practice. Finally, the method is not suited to
assess effects of different external loading modes and is therefore
difﬁcult to use in a clinical setting where clinicians would like
to advise the patient as to which daily activities can be safely
performed and which may lead to bone fracture.
The other promising tool for the prediction of fracture risk in
metastatic bone disease is patient-speciﬁc ﬁnite element (FE) analy-
sis. Although this method is widely studied to calculate the fracture
risk in osteoporosis (for example (Bessho et al., 2009; Keyak et al.,
2013; Kopperdahl et al., 2013; Orwoll et al., 2009)), few groups have
used it for assessing failure load in metastatic bone disease in the
femur (Cheal et al., 1993; Derikx et al., 2012; Keyak et al., 2005a,
2007; Spruijt et al., 2006; Tanck et al., 2009). Cheal et al. (1993) were
one of the ﬁrst to use FE modelling for this purpose. Unfortunately,
they found large differences between the calculated failure loads and
the failure loads measured in their experiments. These inferior
results may be explained by the fact that they used a femoral FE
model based on average anatomy and material behaviour data (Cheal
et al., 1993), and therefore did not capture the relevant biomechanical
differences that exist amongst bones of different subjects.
Some years later, Keyak and co-workers developed and exten-
sively validated a full workﬂow for patient-speciﬁc FE modelling
based on QCT images. They empirically established relationships
between CT values and bone material properties (Keyak et al.,
1996). Subsequently, in a mechanical test setup they loaded intact
cadaver femurs until failure and found good agreement between
the experiments and the FE simulations (Keyak, 2001; Keyak et al.,
2005b). Additionally, they applied this workﬂow to femurs with
simulated and actual metastatic lesions (Keyak et al., 2005a, 2007)
and were able to accurately predict bone strength (r¼0.97, r¼0.98
and r¼0.94, for intact femurs, and femurs with simulated and
actual lesions, respectively) (Keyak et al., 2005a).
Building on the work by Keyak et al. (2005b), we have developed
and validated a workﬂow for generating subject-speciﬁc ﬁnite
element models. For the validation of our model, we experimentally
tested 10 paired femurs under axial loading conditions (Derikx et al.,
2012; Tanck et al., 2009). Before testing, we retrieved QCT scans of
these femurs, on the basis of which we generated subject-speciﬁc FE
models. The axial loading conditions from the experiments were
mimicked, and the FE models were able to accurately predict the
experimental failure load (R2¼0.90 for intact femurs and R2¼0.93
for metastatic femurs). We additionally showed that, under these
simple loading conditions, FE models can outweigh the performance
of clinical experts (Fig. 2) (Derikx et al., 2012). By implementing more
realistic material behaviour, we were able to further improve the
prediction of failure locations (Derikx et al., 2011). Although results
were very promising in a cadaver study, it is still unclear if these
methods can also improve fracture risk assessment in patients.
Currently, we are running a ﬁrst prospective study to test if these
FE approaches can improve upon standard clinical guidelines with
regard to the prediction of bone fractures in patients. In this
prospective cohort study, including 66 patients with femoral bone
metastases, nine femurs fractured during follow-up. Preliminary
results for 23 of these patients (with ﬁve fractures in three patients)
show that the mean load capacity in the fracture group is sig-
niﬁcantly lower than in the non-fracture group, but conﬁdence
intervals between groups overlap. This indicates that the predic-
tions are not yet accurate enough on patient level, which obviously
is required for implementation in clinical practice. These prelimin-
ary results also show that FE models, with model deﬁnitions as
applied in the cadaver study, are currently able to identify fracture
cases and non-fracture cases with a sensitivity and speciﬁcity in the
same order as previous clinical guidelines. Fortunately, a number of
these model deﬁnitions can be further improved to better suit
in vivo fracture risk assessments. As a result, the number of over-
and undertreated patients could decrease, so that the FE models
could outperform existing clinical guidelines. This would render the
method safe to start clinical trials in which the FE models are used
for making clinical treatment decisions.
4. Future opportunities for FE analysis in clinical fracture risk
assessments
While current simulation results are promising, there are a
number of opportunities to further improve the predictive capa-
city of these models.
First of all, it is important to develop realistic loading conditions
(using musculoskeletal modelling) and to couple them to FE-models.
This would enable modelling of actual daily life activities, which
could lead to more tailored fracture risk predictions. For example, the
femoral load capacity of a femur under axial loading would be greatly
affected by a lesion in the medial shaft, but far less by a lesion in the
greater trochanter. The latter case would have a great inﬂuence on
the bone strength if the applied loading condition included the
abductor muscles. It should be noted, however, that the use of such
musculoskeletal models is not straightforward and may in turn lead
to (additional) errors entering the model (Lund et al., 2012). Hence,
the subsequent effect on the accuracy of the fracture risk predictions
should be elucidated.
Secondly, metastatic bone tissue may require adapted material
models. The material models used in FE modelling are generally based
on empirical studies investigating the relationship between CT inten-
sity and material behaviour of healthy bone tissue, as is the case in our
FE models. Yet, the composition and consequent material behaviour of
diseased bone tissue may be rather different from healthy tissue.
Although Keyak et al. (2005a) showed that the use of the healthy
material model is valid, adapted material models may be needed in
case of extensive sclerotic or mixed type lesions.
In addition, the transition from modelling cadaver experiments to
in vivo fracture risk assessments using FE models should be done with
caution. When scanning patients in vivo, bony structures and soft
tissues affect the CT attenuation in the femur. These effects are
obviously dependent on anatomy and are therefore patient-speciﬁc.
In order to minimise these beam hardening effects, a calibration
phantom should be used, which enables to establish patient-speciﬁc
or even image-speciﬁc calibration lines for converting CT intensities to
calcium equivalent values.
It may be challenging to performmulticentre studies and deal with
subsequent differences in CT images. These centres probably use CT
scanners frommultiple manufacturers, who apply different algorithms
to reconstruct the CT images. Robust calibration procedures are
needed to correct for these differences in order to reliably establish
material properties. Recent work by Carpenter et al. (2014) showed
large differences in calculated femoral bone strength based on QCT
images retrieved from two different scanners, especially under single
leg stance loading (mean difference -1100 N, 95% CI between 390 and
-2526 N, approximately; independent of femoral strength). The use of
hydroxyapatite calibration phantoms could not sufﬁciently correct for
these differences between scanners. Obviously, such measurement
errors are unacceptable when using FE predictions for clinical decision
making on a patient-speciﬁc basis, and rigorous alternative calibration
protocols should be developed for multicentre studies.
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Another opportunity to improve the predictive capacity is the
implementation of anisotropic material behaviour of bone. Since bone
anisotropy cannot be quantiﬁed using a clinical CT resolution, con-
siderable work should be done on multi-level modelling in order to
ﬁnd a proper way of implementing these mechanical properties in a
patient-speciﬁc manner. The ﬁrst steps in that direction have been
taken by Hazrati Marangalou et al. (2013). Although their ﬁndings
were not yet conﬁrmed using clinical CT images, the results were
promising and suggest that extrapolating anisotropic material beha-
viour frommicro-level CT data to macro-level FE models is possible. In
addition, imaging techniques are vastly improving, and it is only a
matter of time before this micro-level information can be gleaned
from clinical CT images with a radiation dose acceptable for in vivo
scanning. Alternatively, pre-clinical research on bone specimens
showed that ultrasound can be used to determine the structural
properties of bone (Lin et al., 2012). However, whether this new
technique is applicable in vivo as well, remains to be seen.
From a more practical point of view, the workﬂow for fracture
risk assessment using FE models should be accelerated beyond a
clinically acceptable limit. Clinical implementation is currently
hampered by the fact that the procedure to calculate the fracture
risk needs speciﬁc modelling software and engineering knowledge.
In order to make these mechanical tools available for experts in
clinical practice, the workﬂow should be further automated.
A promising method to do so is probabilistic modelling (Taylor
et al., 2013), which would use principal component analysis to
select characteristics from the FE models that are statistically
predictive for the fracture risk. If these signiﬁcant components are
determined for every patient, the statistical model can be used to
calculate the individual fracture risk. In this way, the extensive
patient-speciﬁc modelling becomes redundant, and the fracture risk
assessment will be accelerated to a clinically acceptable time span.
By addressing the opportunities mentioned above, further
improvements on in vivo fracture risk predictions can be estab-
lished, which will lead to decreased numbers over- and under-
treated patients. Obviously, the FE models can only be introduced
into clinical practice if they outperform existing guidelines. Since
these guidelines poorly predict the patient-speciﬁc fracture risk,
there is room for improvement of clinical decision making using
mechanical models. Hence, although the validity of these models
is not yet perfect, in the near future they may become of great
added value. There is no doubt that with the modelling and
imaging opportunities ahead, these tools will ﬁnd their way to
clinical practice in the very near future.
5. Conclusion
In this paper we discussed the clinical practice of metastatic bone
disease, which lacks an accurate predictor for the fracture risk.
Fig. 2. Clinical experts ranked intact femurs (squares) and femurs with artiﬁcial lytic lesions (circles) on bone strength. Their rankings poorly agreed with the actual ranking
on bone strength as determined from mechanical experiments. The ranking based on the FE model far better resembled the experimental results. Reproduced with
permission and copyright© of the British Editorial Society of Bone and Joint Surgery [Derikx LC, van Aken JB, Janssen D, et al. The assessment of the risk of fracture in femora
with metastatic lesions: comparing case-speciﬁc ﬁnite element analyses with predictions by clinical experts. J Bone Joint Surg [Br] 2012;94-B:1135–1142. (Supplementary
ﬁgure b)].
L.C. Derikx et al. / Journal of Biomechanics 48 (2015) 761–766764
Current scoring systems omit mechanical parameters (such as initial
bone strength) that are crucial for sound fracture risk assessments,
and therefore result in relatively high numbers of over- and under-
treated patients. Alternatively, biomechanical tools, such as CTRA and
FE modelling, have been proposed for clinical fracture risk assess-
ment in metastatic bone disease. In an experimental setting, both
methods show promising results; FE models have shown to outper-
form clinical experts. Obviously these models need to proof their
beneﬁt in clinical trials before this technology can be made available
for clinical experts treating patients with metastatic bone disease.
This transition to in vivo fracture risk assessment is challenging, but
there are a number of modelling and imaging opportunities to
further improve the predictive capacity of these models. With such
improvements ahead, these tools may become of great added value
for the fracture risk assessment in metastatic bone disease and as
such will ﬁnd their way to clinical practice.
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Note from the authors
Rik loved science. Rik was science. He enjoyed discussing and
developing theories about the mechanisms of bone adaptation and
taught us the basics of Wollf's law. Nowadays, we ourselves teach
students, in Rik's spirit, how bone adapts and often use the phrase
‘use it or lose it' which Rik used on many occasions. In this paper we
focus on metastatic bone disease, a devastating illness in which bone
is resorbed by cancer cells and normal bone adaptation rules do not
apply anymore. Although Rik favoured fundamental research, he
deﬁnitely stimulated applied research. Not because he wished to be
involved but mainly because he saw the urgency to improve the
connexion between biomechanics and clinical practice. The research
within the lab in Nijmegen has progressed in his spirit and we still
feel the presence of his critical and stimulating mind. We hope to
make him proud!
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